Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference, January 9-12, 2023, at The Westin St. Francis, San Francisco, California. In connection with the conference, there will be a webcast of the Company’s presentation available on the Company’s website starting at 2:15 p.m. Pacific Time/4:15 p.m. Central Time on Tuesday, January 10, 2023.
The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investor Relations” link. A replay of the presentation will also be available on the Company’s website for thirty days.
About Acadia Healthcare
Acadia is a leading provider of behavioral healthcare services across the United States. As of November 30, 2022, Acadia operated a network of 246 behavioral healthcare facilities with approximately 10,800 beds in 39 states and Puerto Rico. With more than 22,500 employees serving approximately 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Last Trade: | US$24.53 |
Daily Change: | 0.76 3.20 |
Daily Volume: | 2,714,959 |
Market Cap: | US$2.270B |
August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load